<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01510509</url>
  </required_header>
  <id_info>
    <org_study_id>TITANIC-XV</org_study_id>
    <nct_id>NCT01510509</nct_id>
  </id_info>
  <brief_title>The Titan Versus Everolimus Intracoronary Stent (Xience V) in Diabetic Patients</brief_title>
  <acronym>TITANIC-XV</acronym>
  <official_title>TITANIC-XV Trial: Prospective, Multicenter and Randomized Trial (Bioactive Bare Metal Titanium Stent Versus Everolimus Drug Eluting Stent)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Infanta Cristina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Infanta Cristina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Even though the safety of drug eluting stents has been long established, in roughly 25% o
      patients their implantation is not considered, for specifically clinical reasons (chronic
      anticoagulation, bleeding, etc…), which make prolonged use of clopidogrel unsuitable. A
      considerable percentage of these patients have diabetes mellitus, a well known risk factor
      for stent thrombosis. Recently, the special characteristics of the titanium stent with nitric
      oxide have been described, causing it to be considered as a bioactive stent.

      The TITANIC-XV trial was a prospective randomized multi-center active-treatment-controlled
      clinical trial, with the chief aim to evaluate clinical outcome after titanium bare metal
      stent (Titan2®, Hexacath, Paris, France) implantation as compared with everolimus drug
      eluting stent (Xience-V®, Abbott Vascular, Santa Clara, California, USA) in diabetic patients
      undergoing percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac events</measure>
    <description>Comparison of major adverse cardiac events defined as death, non fatal myocardial infarction, brain stroke or new revascularization at 1, 6, 12 and 24 months follow-up between the two treatment strategies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late luminal loss</measure>
    <description>Comparison of late luminal loss within the in-segment zone at 9 months between the two treatment strategies in the subgroup of patients with angiographic follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Diabetes Mellitus</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>Titanium bare metal stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titanium bare metal stent (Titan2®, Hexacath, Paris, France)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus Drug Eluting Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xience-V®, Abbott Vascular, Santa Clara, California, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Titanium bare metal stent (Titan2®)</intervention_name>
    <description>Titan2®, Hexacath, Paris, France</description>
    <arm_group_label>Titanium bare metal stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus Drug Eluting Stent (Xience-V®)</intervention_name>
    <description>Xience-V®, Abbott Vascular, Santa Clara, California, USA</description>
    <arm_group_label>Everolimus Drug Eluting Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  Diabetes mellitus according to the World Health Organization Report

          -  Percutaneous coronary intervention due to at least one significant de novo lesion
             (defined as at least 50% diameter stenosis by visual estimation) in a native coronary
             artery or coronary bypass graft.

          -  Informed Consent &quot;signed&quot;

        Exclusion Criteria:

          -  Inclusion in another clinical research protocol

          -  Pregnancy

          -  STEMI within 48 hours

          -  Unprotected left main disease

          -  Restenotic lesions

          -  Stent diameter &lt; 2,5 mm or &gt; 3,5 mm

          -  Stent length more than 28 mm in &lt; 3 mm vessels

          -  Chronic total occlusions

          -  Allergy to aspirin, clopidogrel, heparin or abciximab

          -  Active bleeding or a significant increase in bleeding risk

          -  Significant renal insufficiency defined as creatinine &gt; 2 mg/dl

          -  Severely depressed LV function (EF≤35%)

          -  Cardiogenic shock

          -  Ischemic stroke within the last 6 months

          -  Contraindication for DES

          -  Disease with life expectancy &lt; 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Ramon Lopez-Minguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Infanta Cristina (Badajoz, Spain). Interventional Cardiology Department.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center, Satakunta Hospital, Pori, Finland</name>
      <address>
        <city>Satakunta</city>
        <state>Pori</state>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Torrevieja</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03180</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerto Real de Cádiz</name>
      <address>
        <city>Puerto Real</city>
        <state>Cadiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Ramón Jiménez de Huelva</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud de Toledo</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2012</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Infanta Cristina</investigator_affiliation>
    <investigator_full_name>Jose Ramon Lopez Minguez</investigator_full_name>
    <investigator_title>MD, PhD, Chief of Interventional Cardiology Deparment</investigator_title>
  </responsible_party>
  <keyword>Drug Eluting Stent</keyword>
  <keyword>Bioactive Bare Metal Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

